Non-ownership Filings
ODAC reviewed Imfinzi in resectable lung cancer | Jul. 26, 2024 |
Half-year Report | Jul. 25, 2024 |
Acquisition of Amolyt Pharma completed | Jul. 15, 2024 |
Total Voting Rights | Jul. 01, 2024 |
Lynparza & Imfinzi positive CHMP in endometrial | Jul. 01, 2024 |
Update on Imfinzi ADJUVANT BR.31 trial | Jun. 25, 2024 |
Imfinzi improved EFS and OS in bladder cancer | Jun. 25, 2024 |
Ownership Update Filings
Director/PDMR Shareholding | Jun. 12, 2024 |
Director/PDMR Shareholding | May. 15, 2024 |
Director/PDMR Shareholding | Mar. 12, 2024 |
Director/PDMR Shareholding | Mar. 06, 2024 |
Director/PDMR Shareholding | Mar. 06, 2024 |
Director/PDMR Shareholding | Feb. 22, 2024 |
Director/PDMR Shareholding | Dec. 14, 2023 |